Gefitinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR), has
been used to treat numerous cancers; however, evidence has shown that cancer cells can
become resistant to gefitinib during therapy. Here, we report a human proto-oncogene,
securin, which displays resistance to death in cancer cells. Gefitinib treatment decreases
securin levels at the protein level by inducing protein instability but did not affect on the
securin gene expression. Treatment with gefitinib induced cytotoxicity in various human …